Search:

Search for text in:

separate each search
term with a space

Multiple terms:

Additional Search Filters:

Conference Years:

Days Within Meeting:

Session Type:

Participation Type:

HIVR4P Home

HIVR4P 2016 is made possible in part by the generous support of the American people through 1 R13 AI122959-01 from the National Institute of Allergy and Infectious Diseases (NIAID), and from the United States Agency for International Development (USAID). The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services or USAID; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.

  • Sort by:
  • Browse by:
<< first | < prev page: of 1 records per page: next > | last >>
pages: 1 sessions: 1 to 1 of 1
Satellite Session: HIV Vaccine Design and Development Partnerships in Africa: Showcasing African-led Basic HIV Prevention Science Research
Introduction and Welcome of Speakers
Pontiano Kaleebu
Medical Research Council/Uganda Virus Research Institute
Introduction and Welcome of Speakers
Peter Dukes
Africa Research Excellence Fund, The Gambia/Uganda/UK
VISTA model: Introduction
Jill Gilmour
International AIDS Vaccine Initiative
VISTA model: Transmission of multiple HIV-1 founder viruses with high level of recombination in MSM
Gladys Macharia
Kenya Medical Research Institute
VISTA model: Viral diversity, evolution and innate responses during acute HIV-1 infection and their association with disease pathogenesis
Amin Hassan
Kenya Medical Research Institute
MRC model South Africa: Developing Research Capacity & Addressing Transformation in RSA
Glenda Gray
Medical Research Council, South Africa
MRC model South Africa: Emerging findings in pox-protein HIV vaccine trials in South Africa
Fatima Laher
Perinatal HIV Research Unit, Chris Hani Baragwanath Hospital, South Africa
MRC model South Africa: Viral variants that initiate and drive the maturation of broadly neutralizing V1V2 antibodies
Jinal Bhiman
National Institute for Communicable Diseases, South Africa
EDCTP model: Introduction
Thomas Nyirenda
Eurpean & Developing Countries Clinical Trials Partnership
EDCTP model: Ex-vivo stimulation with HIV-1-specific antigens support the existence of NK-cell recall responses
Sabelle Jallow
Medical Research Council, The Gambia
EDCTP model: Enhanced Immunogenicity of oligomannose HIV-1env gp120 vaccines
Loveline Ngu
The Chantal Biya International Reference Center for Research on HIV/AIDS, Messa Yaounde, Cameroon
Q&A: Co-Chair
Pontiano Kaleebu
Medical Research Council/Uganda Virus Research Institute
Q&A: Co-Chair
Peter Dukes
Africa Research Excellence Fund, The Gambia/Uganda/UK
Q&A: Discussant
Sabelle Jallow
Medical Research Council, The Gambia
Q&A: Discussant
Glenda Gray
Medical Research Council, South Africa
Q&A: Discussant
Jinal Bhiman
National Institute for Communicable Diseases, South Africa
Q&A: Discussant
Jill Gilmour
International AIDS Vaccine Initiative
Achieving well-balanced partnerships: the AREF experience
Peter Dukes
Africa Research Excellence Fund, The Gambia/Uganda/UK
Launch of African AIDS Vaccine Virtual Network - Mission and Vision
Pontiano Kaleebu
Medical Research Council/Uganda Virus Research Institute
Panel Discussion: Co-Chair
Margaret McCluskey
US Agency for International Development
Panel Discussion: Co-Chair
William Snow
Global HIV Vaccine Enterprise
Panelist
Steven Wakefield
HIV Vaccine Trials Network
Panelist
Nelson Michael
U.S. Military HIV Research Program
Panelist
Nina Russell
Bill and Melinda Gates Foundation
Panelist
Claire Rekacewicz
Agence Nationale de Recherche sur le Sida et les hépatites virales, France
Panelist
Elioda Tumwesigye
Minister of Science and Technology, Uganda
Panelist
Mary Marovich
U.S. National Institutes of Health
Panelist
Thumbi Ndung’u
University of KwaZulu Natal, South Africa
Panelist
Deenan Pillay
Africa Health Research Institute, South Africa
from HIV Research for Prevention 2016 on 17 October 2016 08:30-12:30
<< first | < prev page: of 1 records per page: next > | last >>
pages: 1 sessions: 1 to 1 of 1